These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29745930)

  • 1. [EMDA with MMC. Critical review.].
    Solsona E
    Arch Esp Urol; 2018 May; 71(4):409-416. PubMed ID: 29745930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Riedl C
    World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravesical therapy with mitomycin through electromotive drug administration].
    Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
    Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
    Carando R; Zazzara M; Cotrufo S; Ludovico GM
    Urol Int; 2019; 103(3):285-290. PubMed ID: 31461726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
    Decaestecker K; Lumen N; Van Camp C; Oosterlinck W
    Acta Clin Belg; 2018 Oct; 73(5):324-327. PubMed ID: 29451102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
    Cho IC; Kim EK; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
    Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
    Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gutiérrez Tejero F; Pareja Vílchez M; Arrabal Martín M
    Bladder Cancer; 2023; 9(2):159-166. PubMed ID: 38993293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients.
    Carando R; Soldini E; Cotrufo S; Zazzara M; Ludovico GM
    Arab J Urol; 2020 Aug; 19(1):71-77. PubMed ID: 33763251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
    Rehme C; Niedworok C; Rübben H; Vom Dorp F
    Urologe A; 2015 Feb; 54(2):235-8. PubMed ID: 25316185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
    Kaasinen E; Wijkström H; Rintala E; Mestad O; Jahnson S; Malmström PU
    Scand J Urol; 2016 Oct; 50(5):360-8. PubMed ID: 27603424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.